evotec

Focusing on high-value research and collaborations



The future of Evotec

- A drug research and development company
- Focused on neuroscience and related areas for proprietary programs
- A powerful and deep drug discovery platform for high-value collaborations in many therapeutic areas
- A belief in differentiated science as the core driver of success
- A partnership and licensing business

Rationale for the transaction

- Concentrate on higher value pipeline expansion
- Additional EUR 46 million cash through the divestment of non-core areas:
  - Chemical process development, cGMP pilot plant and drug formulation
- Good prospects for divested operations with strong commitment by purchaser to growth and investment
- Better career development for transitioning employees in a larger service-minded organization

The Chemical Development business:
Broad range of chem. development and formulation capabilities

Process research & development

Custom synthesis

Analytical services

Pilot Plant manufacture

QA & Regulatory

Formulation

- Novel route process research and development
- Chiral chemistry, salt selection, polymorph screening
- Analytical method development and validation
- Parenteral formulation development
- Sterile manufacture
- Rapid custom synthesis (including cGMP)
- cGMP scale-up and regulatory support
- cGMP manufacture for Clinical Ph I, II, III

evotec

Powerful research capabilities up to proof-of-concept

Fragment Based Drug Discovery	High Throughput Fragment Screening I Fragment to Lead
Assay Development & Screening	Assay Development I Medium Throughput Screening High Throughput Screening I Screening Library I High Content Screening Compound Profiling I High Throughput Fragment Screening
Medicinal Chemistry	Structural Biology I Target Class Expertise I Hit to Lead & Lead Optimisation I Computational Chemistry I Pharmacokinetics Primary & Secondary Screening Support
Compound Libraries	Library Design I Library Synthesis I Compound Management

Robust small molecule engine with first proof-of-concept in insomnia



Who is Aptuit?

- **Aptuit**, Inc. is a global company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators
- 2,680 employees, 18 global facilities
  - Including Harrisonville, Kansas City (both Missouri), West Lafayette (Indiana), Bangalore, Hyderabad, Vizag (India), Edinburgh (Scotland)
- Intention to keep the core business at Oxford
  - Will employ Evotec's administrative services for a transitional period
- Completes drug development services of Aptuit in all three major geographics – Europe, North America, Asia
  - Positions Aptuit to transfer to commercial scale in India
- www.aptuit.com

Sale of Chemical Development to Aptuit for £ 31.5m in cash

- Agreement signed on 10 Sept 2007, anticipated closing within 75 days
- Sale of all assets of Oxford based Chemical Development business and of all shares of Evotec (Scotland) Ltd.
- Purchase price of £ 31.5m (approx. € 46.4m; US$ 63.9m)
  - Valuation: 1.7 x 2006 revenues
- All employees transfer with the purchase (approx. 210)
  - 64 Evotec (Scotland) Ltd employees/facilities
  - All employees of the Chemical Development business under TUPE and some overhead employees in Oxford
- Several long-term property leases will be transferred to Aptuit
- Evotec will provide financial and IT services during the transition
- Aptuit will provide chemical development services to Evotec

evotec

Preliminary P&L Services Division

Mio €	01-06/2007 Continued operations	01-06/2007 Discontinued operations	01-06/2007 Total	01-06/2006 Continued operations	01-06/2006 Discontinued operations	01-06/2006 Total
Total revenues	15,3	12,7	28,0	18,1	12,0	30,1
Gross profit	2,7	3,2	5,9	5,6	4,0	9,6
Gross margin	18%	25%	21%	31%	33%	32%
- R&D	0,7	-	0,7	1,4	-	1,4
- SG&A	5,5	1,8	7,3	5,7	1,3	7,0
- Other operating expense	0,3	-	0,3	0,9	-	0,9
- Other operating income	(0,3)	-	(0,3)	-	-	-
Operating income (loss)	(3,5)	1,4	(2,1)	(2,4)	2,7	0,3

Note: SG&A allocation is still preliminary and may vary up to 10%

Guidance “continued business” 2007

Revenue guidance:	€ 30 – 35m (approx. US$ 41 – 48m)
Cash guidance:	€ 93 - 98m (approx. US$ 128 – 135m)
Non operating income*:	approx. € 25m (approx. US$ 35m)

Note: All exchanges are based on exchange rates of 10 September 2007

Summary

- Disposal aligns with strategic direction of Evotec
- Strong cash position reduces risk and provides long run-rate
- Reduction of complexity and fixed costs
- Opportunity to transform non-core assets for core assets

- Evotec vision: To become an emerging pharmaceutical company with a strong pipeline focused on CNS related diseases and powerful partnerships in research and drug development


Evotec
Pharma
Innovation Pool